AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
ABBV News
On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management named Netflix, Inc. NFLX as his final trade. On the earnings front, Netfli...
recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's...
BofA raised the firm’s price target on AbbVie (ABBV) to $204 from $200 and keeps a Neutral rating on the shares following what the firm calls a “decent quarter”...
Analyst ratings
62%
of 29 ratingsMore ABBV News
AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, pushing AbbVie’s stock up 3.15% on the...
...
As more economists raise their recession forecast and consumer sentiment wanes, wrinkles and thin lips might be the least of our worries. AbbVie, the largest B...
AbbVie Inc.'s ABBV stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast. The company reported an adjusted EP...
AbbVie rises as it beats Wall Street estimates, raises 2025 outlook AbbVie raised its profit outlook for 2025 after reporting sales and profit that beat Wall S...
William Blair analyst Matt Phipps has maintained their bullish stance on ABBV stock, giving a Buy rating on April 22. Matt Phipps has given his Buy rating due...
Biopharmaceutical company AbbVie (ABBV) saw its stock jump on Friday following the release of its Q1 2025 earnings report. The company reported adjusted diluted...